UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 

Date of Report (Date of earliest event reported): May 12, 2021

 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-56035 46-2316220
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)

 

1402 N. El Camino Real

San Clemente, CA

92672
(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code (714) 392-9752

N/A
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Section 1 - Registrant’s Business and Operations 

Item 1.01 Entry into a Material Definitive Agreement.

 

On May 12, 2021, Global Wholehealth Partners Corporation (the “Company”) executed an Agreement with Dr. AnhDao Vu Le (“Dr. Le”) dated January 12, 2021. The delay in executing the Agreement was a direct result of the COVID 19 pandemic. Under the terms of the Agreement, the Company has engaged Dr. Le to serve as medical director of the CLIA labs. This Agreement will allow the Company to open up a CLIA WAIVED LAB and do mobile COVID 19 testing and other CLIA WAIVED tests. The foregoing description of the Agreement does not purport to be completed and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Section 9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.

Exhibit No. Document Location
10.1 Agreement between Global WholeHealth Partners Corp and Dr. AnhDao Vu Le Filed Herewith

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Registrant)

 

Date: May 14, 2021

By: /s/ Charles Strongo
Charles Strongo

Chief Executive Officer